^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Published date:
02/14/2022
Excerpt:
Overall, 12 partial responses were achieved, most commonly in cholangiocarcinoma (n=5) as well as in a broad spectrum of tumors including head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, and non-small cell lung cancer (each n=1); median duration of response was 7.3 months (95% confidence interval [CI], 3.3-14.5). Overall response rate was highest for patients with FGFR fusions/rearrangements (n=5; 25.0% [95% CI, 8.7-49.1]), followed by those with FGFR mutations (n=3; 23.1% [95% CI, 5.0-53.8]).
DOI:
10.1016/j.annonc.2022.02.001
Trial ID: